Literature DB >> 19750378

[Prevalence of respiratory symptoms and associated factors: a population-based study in adults from Lages, Santa Catarina State, Brazil].

Adriane Cristina Bernat1, Maria Conceição de Oliveira, Gino Chaves da Rocha, Antonio Fernando Boing, Karen Glazer Peres.   

Abstract

A cross-sectional population-based study was conducted in Lages, Santa Catarina State, Brazil, in order to estimate the prevalence of symptoms of chronic bronchitis, breathlessness, and wheezing and associated factors in a sample of adults 20 to 59 years of age (n = 2,051). The study employed a cluster sample design and Poisson regression analyses. Prevalence rates for chronic bronchitis, breathlessness, and wheezing were 5%, 35.7%, and 20.2%, respectively. The adjusted analysis showed chronic bronchitis associated with low schooling, smoking, and hospital admissions due to respiratory illness during childhood. Breathlessness was associated with female gender, low schooling and family income, non-white race, hospital admissions due to respiratory illness during childhood, smoking, and occupational exposure to dust. Wheezing was associated with female gender, low schooling and family income, non-white race, hospital admissions due to respiratory illness during childhood, smoking, and occupational exposure to dust. Public health planners should consider climatic factors and work activities when developing activities to prevent respiratory diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19750378     DOI: 10.1590/s0102-311x2009000900005

Source DB:  PubMed          Journal:  Cad Saude Publica        ISSN: 0102-311X            Impact factor:   1.632


  1 in total

1.  Trend of self-reported asthma prevalence in Brazil from 2003 to 2013 in adults and factors associated with prevalence.

Authors:  Felipe Moraes Dos Santos; Karynna Pimentel Viana; Luciana Tarbes Saturnino; Evelyn Lazaridis; Mariana Rodrigues Gazzotti; Rafael Stelmach; Claudia Soares
Journal:  J Bras Pneumol       Date:  2018 Nov-Dec       Impact factor: 2.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.